Dysfunctional high-density lipoprotein in chronic inflammatory rheumatic diseases.

Autor: Waldecker-Gall S; Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Germany., Seibert F; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany., Bertram S; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany., Doevelaar A; Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany., Braun J; Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Germany., Baraliakos X; Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Germany., Babel N; Center for Translational Medicine, University Hospital Marien Hospital Herne, Ruhr University Bochum, Herne, Germany., Waldecker C; Department of Nephrology, St. Marien-Hospital Mülheim an der Ruhr, Mülheim, Germany., Scharow L; Department of Cardiology, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany., Pagonas N; Department of Cardiology, University Hospital Ruppin-Brandenburg, Brandenburg Medical School, Neuruppin, Germany., Westhoff TH; Medical Department I, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Hölkeskampring 40, Herne 44625, Germany.
Jazyk: angličtina
Zdroj: Therapeutic advances in musculoskeletal disease [Ther Adv Musculoskelet Dis] 2023 Aug 25; Vol. 15, pp. 1759720X231187191. Date of Electronic Publication: 2023 Aug 25 (Print Publication: 2023).
DOI: 10.1177/1759720X231187191
Abstrakt: Background: The mechanism explaining low cholesterol concentrations in chronic inflammatory rheumatic disease (CIRD) is incompletely understood. We hypothesized that chronic inflammation impairs the functionality of high-density lipoprotein (HDL), for example, by oxidative processes.
Objectives: Assessment of oxidized HDL (HDL ox ), a marker of dysfunctional HDL, in newly diagnosed patients with CIRD before and after initiation of immunosuppressive therapy and comparison of HDL ox values of patients with CIRD to non-CIRD controls.
Design: Prospective observational trial.
Methods: The study was conducted on 44 newly diagnosed CIRD patients, who were initiated on immunosuppressive therapy (baseline). A total of 136 patients without CIRD served as control. Lipid profiles including HDL ox levels and C-reactive protein (CRP) were measured in both groups at baseline. In CIRD patients, measurements were repeated 12 weeks after baseline. Validated outcome tools for disease activity and function were assessed at baseline and 12 weeks.
Results: A total of 33 (75%) patients with rheumatoid arthritis, 7(16%) with axial spondyloarthritis, and 4 (9%) with systemic lupus erythematosus were included. Groups were comparable for age and BMI. CIRD patients had higher HDL ox concentrations (1.57 versus 0.78, p  = 0.02) and tended to have lower low-density lipoprotein cholesterol, HDL cholesterol, and cholesterol concentrations compared to controls. HDL ox (1.57 versus 1.4, p  = 0.26) and CRP levels (2.1 versus 0.7 mg/dl, p  < 0.01) decreased in CIRD patients from baseline to follow-up.
Conclusion: CIRD is associated with an impairment of the anti-inflammatory properties of HDL as reflected by an increase in HDL ox concentrations. This effect may contribute to the increased cardiovascular risk in chronic inflammatory diseases.
Competing Interests: The authors declare that there is no conflict of interest.
(© The Author(s), 2023.)
Databáze: MEDLINE
Externí odkaz: